The reasons that a patient wouldn't continue from LAVENDER to LILAC are: * adverse side effects * deterioration in symptoms.
It makes no difference to the decision to continue from a blinded trial to an open label trial whether the patient experienced zero effect or a positive effect.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)